Skin

Annual Report 2023: LEO Pharma Delivers 10% Revenue Growth and Returns to Positive EBITDA

Retrieved on: 
Thursday, February 29, 2024

LEO Pharma delivers a solid operational performance uplift with double-digit revenue growth and an EBITDA uplift of DKK 2.1 billion, corresponding to a 20%-points margin improvement.

Key Points: 
  • LEO Pharma delivers a solid operational performance uplift with double-digit revenue growth and an EBITDA uplift of DKK 2.1 billion, corresponding to a 20%-points margin improvement.
  • LEO Pharma exceeded our profitability guidance and hit the upper range of our revenue growth guidance provided in March 2023.
  • LEO Pharma delivered 11.4 billion in revenue, corresponding to 7% revenue growth in 2023.
  • LEO Pharma exceeded our profitability guidance and hit the upper range of our revenue growth guidance provided in March 2023.

Exact Sciences Launches Riskguard™ Hereditary Cancer Test in the United States

Retrieved on: 
Wednesday, February 28, 2024

Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, today announced the launch of the Riskguard™ hereditary cancer test in the United States.

Key Points: 
  • Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, today announced the launch of the Riskguard™ hereditary cancer test in the United States.
  • Offering more effective personalized screening solutions supports Exact Sciences’ commitment to help detect cancer earlier.”
    For patients already diagnosed with cancer, knowing about certain gene variants can help create individualized treatment plans for patients.
  • Exact Sciences’ customer care teams are available to help patients explore the testing process and understand possible results and outcomes.
  • The test is processed in Marshfield, WI at PreventionGenetics, an Exact Sciences laboratory qualified to perform high-complexity clinical laboratory testing that has been providing quality genetic testing since 2004 and joined Exact Sciences in 2022.

Range Energy Announces $23.5 Million in New Financing to Accelerate On-Road Decarbonization with Electric Powered Commercial Trailers

Retrieved on: 
Wednesday, February 28, 2024

Range Energy (Range), the hardware company bringing powered trailers to the commercial trucking market, today announced $23.5 million in new funding led by Phillip Sarofim’s Trousdale Ventures , with participation from UP.Partners , R7 , and Yamaha Motor Ventures .

Key Points: 
  • Range Energy (Range), the hardware company bringing powered trailers to the commercial trucking market, today announced $23.5 million in new funding led by Phillip Sarofim’s Trousdale Ventures , with participation from UP.Partners , R7 , and Yamaha Motor Ventures .
  • Range will use this fresh capital to accelerate its work on customer pilot programs in parallel with advancing towards full-scale production of its electric powered trailers, which are essential to the decarbonization of commercial fleets under pressure to meet emerging emissions reduction targets.
  • Today’s additional financing brings Range’s total funding to $31.5M inclusive of the company’s $8M seed financing .
  • View the full release here: https://www.businesswire.com/news/home/20240228744525/en/
    Range Energy's electric powered commercial trailer (Photo: Business Wire)
    “Commercial-led innovation is material for achieving the electrification of on-road transportation.

Global Self Tanning Products Market Trends Report 2024 with Forecasts to 2029: Rising Popularity of Organic, Natural, and Vegan-based Products and Increasing Focus on Men's Self-tanning Products - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 28, 2024

As an alternative to traditional tanning methods, self-tanning products have gained popularity for providing a convenient and safer way to achieve a bronzed complexion.

Key Points: 
  • As an alternative to traditional tanning methods, self-tanning products have gained popularity for providing a convenient and safer way to achieve a bronzed complexion.
  • The report provides the bifurcation of the market into three segments based on the product type: Lotions, Gels, and Others.
  • The report provides the glimpse of the self tanning products market based on the following category: Conventional and Natural & Organic.
  • The global self tanning products market is fragmented, with a diverse range of products offered by numerous brands catering to different consumer preferences, skin types, and desired outcomes.

Galderma Announces Record 2023 Net Sales of Over 4 B USD and Significant Core EBITDA Margin Expansion

Retrieved on: 
Thursday, February 29, 2024

2023 margin expansion was driven by gains from premiumization, structural cost savings, and operating expenses leverage, partially offset by nemolizumab investments.

Key Points: 
  • 2023 margin expansion was driven by gains from premiumization, structural cost savings, and operating expenses leverage, partially offset by nemolizumab investments.
  • On 26 June 2023, Galderma announced a private placement of approximately 1 B USD from a group consisting of current shareholders, new investors, as well as management.
  • Cetaphil, with over 75 years of heritage in sensitive skincare, surpassed a record 1 B USD in net sales in 2023.
  • In 2023, Galderma further consolidated its ESG profile by rolling out a dedicated executive-level ESG oversight and instituting the ESG Council.

Advancing Skin Cancer Detection: American Academy of Dermatology Journal Publishes DermaSensor's Breakthrough Melanoma Detection Results From A Major, Multicenter Trial

Retrieved on: 
Wednesday, February 28, 2024

In addition, the Negative Predictive Value (NPV) of 98.1% (95% CI, 91.8%-99.6%) indicates a high level of reliability for a negative device result of “Monitor”.

Key Points: 
  • In addition, the Negative Predictive Value (NPV) of 98.1% (95% CI, 91.8%-99.6%) indicates a high level of reliability for a negative device result of “Monitor”.
  • For a positive device result of “Investigate Further”, a 1-10 score is also provided to indicate the degree of similarity to malignant lesions.
  • The study found that the likelihood of melanoma for these positive results ranged from 10.3% for low scores (i.e., 1-3) to 47.4% for high scores (i.e., 8-10).
  • This automated, objective device can help in the fight against skin cancer, and the DermaSensor team is dedicated to making a meaningful contribution to its detection and prevention."

VTEX Reports Fourth Quarter 2023 Financial Results

Retrieved on: 
Tuesday, February 27, 2024

VTEX (NYSE: VTEX), the global enterprise digital commerce platform, today announced results for the fourth quarter of 2023 ended December 31, 2023.

Key Points: 
  • VTEX (NYSE: VTEX), the global enterprise digital commerce platform, today announced results for the fourth quarter of 2023 ended December 31, 2023.
  • Geraldo Thomaz Jr., founder and co-CEO of VTEX, commented, “In 2023, we consistently surpassed expectations quarter after quarter, navigating an uncertain economic landscape.
  • Non-GAAP subscription gross margin was 78.6% in the fourth quarter of 2023, compared to 73.5% in the same quarter of 2022.
  • Non-GAAP income from operations was US$11.6 million during the fourth quarter of 2023, compared to a Non-GAAP income from operations of US$1.7 million in the third quarter of 2023 and a Non-GAAP income from operations of US$2.1 million in the same quarter of 2022.

Galderma to Showcase Latest Updates From Its Broad, Innovative and Leading Dermatology Portfolio at the 2024 American Academy of Dermatology Annual Meeting

Retrieved on: 
Wednesday, February 28, 2024

Galderma, the pure-play dermatology category leader, will be showcasing its latest clinical and educational efforts at the American Academy of Dermatology (AAD) Annual Meeting from March 8-12, 2024, highlighting its broad, innovative and leading dermatology portfolio.

Key Points: 
  • Galderma, the pure-play dermatology category leader, will be showcasing its latest clinical and educational efforts at the American Academy of Dermatology (AAD) Annual Meeting from March 8-12, 2024, highlighting its broad, innovative and leading dermatology portfolio.
  • “Our vast presence at AAD combines new data, novel educational activities and patient perspectives, demonstrating how we are putting our commitment to addressing the needs of the dermatology community into action.
  • The event is taking place on Saturday, March 9, in the Pacific Ballroom 21-26, Marriott Marquis San Diego Marina, from 7:00 to 9:00 PM PST.
  • *All presenters are paid consultants or employees of Galderma.

3D Cell Cultures Technologies Report 2024, Featuring Profiles of Leading Market Participants Including Abcam, Agilent Technologies, Corning, Merck, Beckman Coulter and Synvivo - ResearchAndMarkets.com

Retrieved on: 
Monday, February 26, 2024

3D cell culture technologies are a powerful tool for studying cell biology, disease mechanisms and drug discovery.

Key Points: 
  • 3D cell culture technologies are a powerful tool for studying cell biology, disease mechanisms and drug discovery.
  • 3D cell culture models mimic the 3D structure and cell-cell interactions that are found in real tissues, making them more accurate and predictive than traditional 2D cell culture models.
  • There are a variety of 3D cell culture technologies available, including:
    Scaffold-based 3D cell culture: This approach uses a scaffold to provide a 3D support structure for cells to grow on.
  • Bioprinting: This approach uses a 3D printer to deposit cells and biomaterials layer-by-layer to create complex 3D cell culture models.

RION Expands Manufacturing Operations with Cutting-Edge Facility in Rochester, Minnesota

Retrieved on: 
Monday, February 26, 2024

RION, a pioneer in regenerative medicine and exosome technology, has unveiled a major expansion of its manufacturing operations with the inauguration of a state-of-the-art facility in Rochester, Minnesota.

Key Points: 
  • RION, a pioneer in regenerative medicine and exosome technology, has unveiled a major expansion of its manufacturing operations with the inauguration of a state-of-the-art facility in Rochester, Minnesota.
  • Spanning approximately 14,000 square feet, the new facility equips RION with advanced industrial space to ramp up the production of the (plated)™ Skin Science brand.
  • To facilitate the expansion of the new facility, Governor Tim Walz and the Minnesota Department of Employment and Economic Development (DEED) have granted RION funding from the Job Creation Fund and Minnesota Investment Fund.
  • RION stands to receive up to $440,000 from the Job Creation Fund and up to $175,000 from the Minnesota Investment Fund.